| oxaliplatin / Generic mfg. |
STOP-PC, NCT06079346: A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2/3 | 455 | US | OT-101, mFOLFIRINOX | Oncotelic Inc. | Pancreatic Ductal Adenocarcinoma | 06/26 | 06/27 | | |
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2/3 | 700 | US | GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin | Gritstone bio, Inc. | Colorectal Neoplasms | 03/27 | 03/27 | | |
NCT05149807: Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer |
|
|
| Enrolling by invitation | 2/3 | 896 | RoW | SHR-1701 injection, Placebo | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer | 07/27 | 12/27 | | |
NCT05976568: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2/3 | 668 | RoW | QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine, Sintilimab | Qilu Pharmaceutical Co., Ltd. | Hepatocellular Carcinoma | 09/27 | 09/27 | | |
| Recruiting | 2/3 | 1912 | Canada, US | Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month | NRG Oncology, Natera, Inc., National Cancer Institute (NCI) | Stage III Colon Cancer | 03/29 | 03/30 | | |
jRCTs031220572: Phase II study of CapeOX + nivolumab therapy for early recurrent gastric cancer |
|
|
| Recruiting | 2 | 92 | Japan | capecitabine - Generic mfg., Opdivo (nivolumab) - Ono Pharma, BMS, oxaliplatin - Generic mfg. | St. Marianna University Hospital, ONO PHARMACEUTICALO CO., LTD., Bristol-Myers Squibb Company | Early relapsed gastric cancer | | | | |
| Active, not recruiting | 2 | 46 | Japan | docetaxel - Generic mfg., oxaliplatin - Generic mfg. | Yakult Honsha Co.,Ltd. | Gastric cancer | | | | |
RC48-C022, CTR20233553: A phase II clinical study to evaluate the efficacy and safety of injectable vedicitumab plus toripalimab with or without chemotherapy (capecitabine + oxaliplatin) versus chemotherapy for the perioperative treatment of resectable locally advanced gastric/g |
|
|
| Recruiting | 2 | 90 | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, capecitabine - Generic mfg., oxaliplatin - Generic mfg. | Remegen Biopharmaceutical (Yantai) Co., Ltd | HER2-expressing resectable locally advanced gastric/gastroesophageal junction adenocarcinoma | | | | |
2014-001126-15: study to investigate cetuximab plus irinotecan as rechallenge 3rd-line treatment of kras, nras and braf wild-type irinotecan-pretreated metastatic colorectal cancer patients progressing after an initial response to a 1st-line cetuximab-containing therapy and a standard 2nd-line. studio per valutare un ritrattamento con cetuximab e irinotecano in pazienti con tumore del colon-retto metastatico KRAS, NRAS e BRAF wild-type, irinotecano resistenti, progrediti ad una prima linea a base di irinotecano (FOLFIRI o FOLFOXIRI) contenente cetuximab dalla quale abbiano ricevuto un iniziale beneficio |
|
|
| Ongoing | 2 | 27 | Europe | Irinotecan, Cetuximab, Irinotecan, Cetuximab, Concentrate for solution for infusion, Solution for infusion, Erbitux 5mg/ml solution for infusion. | G.O.N.O. (Gruppo Oncologico Nord Ovest), Merck Serono SpA, G.O.N.O. (Gruppo Oncologico Nord Ovest) | metastatic colonrectal cancer KRAS, NRAS and BRAF wild type. carcinoma colon retto metastatico NRAS,KRAS e BRAF non mutato., metastatic tumor of colon-rectum without mutation of genes KRAS, NRAS and BRAF, Diseases [C] - Cancer [C04] | | | | |
2014-000543-33: A trial comparing 2 chemotherapies with personalized treatment with new drugs in patients with colorectal cancer Een studie die twee gepersonaliseerde behandelingen met nieuwe medicijnen vergelijkt bij patiënten met colorectale kanker |
|
|
| Ongoing | 2 | 175 | Europe | Concentrate for solution for infusion, VECTIBIX, AVASTIN, ADRUCIL, ELOXATIN | Antwerp University Hospital, Amgen | metastatic unresectable colorectal cancer (mCRC) ., METASTATIC COLON CANCER, Diseases [C] - Cancer [C04] | | | | |
2005-000970-37: Open, randomized, controlled, multicenter phase II study comparing 5-FU/FA plus oxaliplatin (FOLFOX 4) plus cetuximab versus 5-FU/FA plus oxaliplatin as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer |
|
|
| | 2 | 55 | Europe | Erbitux, EMD271786, Erbitux, Erbitux | Merck KGaA, MERCK S.P.A. | Metastatic colon rectal carcinoma | | 09/10 | | |
2015-003888-10: The purpose of this clinical research is to compare two different treatments to assess whether the use of a single chemotherapy (5-FU) in combination with panitumumab may provide better results in terms of safety and efficacy compared to treatment with two chemotherapy drugs (5 -fluorouracile and oxaliplatin) in combination with panitumumab as first-line therapy in elderly patients (aged =70 years) with cancer without mutations of RAS and BRAF. Lo scopo di questa ricerca clinica è confrontare due diversi trattamenti per valutare se l’utilizzo di un solo chemioterapico (5-fluorouracile) in associazione a panitumumab possa fornire risultati migliori in termini di tollerabilità ed efficacia rispetto ad un trattamento con due farmaci chemioterapici (5-fluorouracile e oxaliplatino) in associazione a panitumumab come terapia di prima linea nei pazienti anziani (età =70 anni) con neoplasia senza mutazioni dei geni RAS e BRAF. |
|
|
| Ongoing | 2 | 180 | Europe | 5 Fluorouracile, Oxaliplatino, acido levo-folinico (L-Leucovorin), Panitumumab, 5 Fluorouracile, Oxaliplatino, acido levo-folinico, Panitumumab, Solution for infusion, FLUOROURACILE TEVA - 500 MG/10 ML SOLUZIONE PER INFUSIONE 1 FLACONCINO DA 10 ML, OXALIPLATINO TEVA - 5MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 40 ML, LEDERFOLIN - 25 MG POLVERE PER SOLUZIONE INIETTABILE PER USO ENDOVENOSO 1 FLACONCINO, VECTIBIX - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 20 ML | Fondazione GONO, Amgen, G.O.N.O. | Metastatic Colorectal Cancer Carcinoma Colorettale metastatico, colorectal cancer spread at distance tumore al colon retto diffuso a distanza, Diseases [C] - Cancer [C04] | | | | |
2015-004849-11: Randomised study to investigate FOLFOXIRI plus Cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE 4.5) Randomisierte Studie zur Untersuchung von FOLFOXIRI plus Cetuximab oder FOLFOXIRI plus Bevacizumab als Erstlinientherapie des BRAF mutierten metastasierten kolorektalen Karzinoms(FIRE-4.5) |
|
|
| Ongoing | 2 | 99 | Europe | Irinotecan, 5-Fluorouracil, Folinic acid, Oxaliplatin, Solution for infusion, Concentrate for solution for infusion, Solution for injection, Concentrate for solution for injection, Erbitux (100 mg), Avastin (100mg), Erbitux (500mg), Avastin (400mg) | University Clinic od Munich-Großhadern (represented by the medical management), Merck Serono GmbH | Histologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum with metastases (metastatic colorectal cancer, mCRC), primarily non-resectable or surgery refused by the patient; RAS wild-type tumour status (KRAS and NRAS exons 2, 3, 4) (proven in the primary tumour or metastasis); BRAF-mutated (V600E) tumour (proven in the primary tumour or metastasis) Histologisch gesichertes Adenokarzinom des Kolons oder Rektums im UICC Stadium IV mit Metastasen (metastasiertes kolorektales Karzinom [mKRK]), Metastasen primär nicht resektabel oder Patient lehnt Operation ab; RAS - Wildtyp-Status (KRAS und NRAS Exone 2,3,4) des Tumors (nachgewiesen in Primärtumor oder Metastase); BRAF mutierter (V600E) Tumor (nachgewiesen in Primärtumor oder Metastase), BRAF-mutated metastatic colerectal cancer, RAS-wildtyp BRAF-mutiertes, metastasiertes Kolorektales Karzinom, RAs-Wildtyp, Diseases [C] - Cancer [C04] | | | | |
2016-003306-13: Peri-operative Immuno-Chemotherapy in Operable oesophageal aNd gastrIc Cancer |
|
|
| Not yet recruiting | 2 | 53 | Europe | Avelumab, Oxaliplatin, Fluorouracil, Folinic acid, N/A, Solution for injection/infusion, Solution for infusion, Avelumab | The Royal Marsden NHS Foundation Trust, Merck Serono Ltd. | Operable oesophageal and gastric cancer, Cancers arising from the oesophagus or the stomach that the doctor thinks can be operated on, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 93 | Europe | FOLFOXIRI + Panitumumab, Vectibix (Panitumumab), folic acid, 5-FU, oxaliplatin, irinotecan, FOLFOXIRI | AIO-Studien-gGmbH, Amgen, ClinAssess GmbH | Metastatic Colorectal Cancer | 06/17 | 01/22 | | |
|
2017-000345-46: Study with anti cancer drugs in patients with resectable parcreatic cancer ¿nITRo trial" Studio con farmaci anti tumorali in pazienti con tumore del pancreas resecabile ¿studio nITRo¿ |
|
|
| Not yet recruiting | 2 | 67 | Europe | oxaliplatino, 5-fluorouracile, lederfolin, Solution for infusion, Powder for solution for infusion, ONIVYDE, OXALIPLATINO ACCORD - 5 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 40 ML, FLUOROURACILE TEVA - 5 G/100 ML SOLUZIONE PER INFUSIONE 1 FLACONCINO DA 100 ML, LEDERFOLIN - 100 MG POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO | CENTRO RICERCHE CLINICHE DI VERONA, Baxalta GmbH | Resectable pancreatic cancer Tumore pancreatico resecabile, Resectable pancreatic cancer tumore del pancreas resecabile, Diseases [C] - Cancer [C04] | | | | |
2017-001845-29: The METIMMOX study - treatment with FLOX chemotherapy with the addition of immune therapy for patients with spread of cancer from the large bowel. |
|
|
| Completed | 2 | 100 | Europe | Opdivo, n/a, Solution for infusion in administration system, , Nivolumab (Opdivo), Oxaliplatin, Fluorouracil, Leucovorin | Akershus University Hospital, Norwegian Cancer Society | Metastatic colorectal cancer, Cancer that has spread to other organs from the large bowel, Diseases [C] - Cancer [C04] | | | | |
2017-003496-54: A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH) Eine randomisierte Multicenterstudie der Phase II zur Ermittlung des optimalen Chemotherapie-Regimes in der Erstlinientherapie von Patienten mit einem metastasierten Pankreaskarzinom |
|
|
| Not yet recruiting | 2 | 270 | Europe | 5-Fluorouracil, Folinic Acid, Oxaliplatin, Gemcitabine, Nab-Paclitaxel, Concentrate for solution for infusion, Infusion, Onivyde | University Hospital, LMU Munich (Germany), Shire International | Histologically (not cytologically) confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma (PDAC) [Stage IV according to UICC TNM edition 8 of 201622: each T, each N, M1] Histologisch (nicht zytologisch) bestätigte Diagnose eines metastasierten duktalen Adenokarzinoms des Pankreas (PDAC) [Stadium IV der UICC TNM Edition 8 von 2016 : jedes T, jedes N, M1], Metastatic pancreatic adenocarcinoma Metastasiertes Adenokarzinom des Pankreas, Diseases [C] - Cancer [C04] | | | | |
2018-002893-38: Phase II Study on NIVolumab in combination with FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan)/Bevacizumab in first line chemotherapy of Advanced COloRectal cancer patients with mutated RAS or BRAF genes. Studio di fase II con Nivolumab in combinazione con FOLFOXIRI (fluorouracile, acido folinico, oxaliplatino e irinotecano)/Bevacizumab come trattamento di I linea in pazienti con tumore colorettale avanzato con mutazione dei geni RAS o BRAF. |
|
|
| Ongoing | 2 | 70 | Europe | Nivolumab, [Nivolumab], Solution for infusion, OPDIVO - 10 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 10 ML- 1 FLACONCINO | GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC), Bristol-Myers Squibb | Advanced colorectal cancer Carcinoma colorettale avanzato, Tumor pathology of the large intestine in advanced stages. Patologia tumorale del grosso intestino in stadio avanzato., Diseases [C] - Cancer [C04] | | | | |
2019-001501-24: Avelumab and Cetuximab and FOLFOXIRI in metastatic colorectal cancer Avelumab più Cetuximab più FOLFOXIRI nel carcinoma del colonretto metastatico |
|
|
| Not yet recruiting | 2 | 58 | Europe | Avelumab, Cetuximab, Fluorouracile, Oxaliplatino, Irinotecan, Calcio levofolinato, [MSB0010718C], [Cetuximab], [Fluorouracile], [Oxaliplatino], [Irinotecan], [Calcio levofolinato], Concentrate for solution for infusion, Solution for injection, Powder for solution for injection, ERBITUX - 5 MG/ML SOLUZIONE PER INFUSIONE - USO ENDOVENOSO- FLACONCINO(VETRO) 20 ML 1 FLACONCINO, Fluorouracile, Oxaliplatino, Irinotecan, Calcio levofolinato | G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST, Fondazione GONO, MERCK SERONO S.p.A | Metastatic colorectal cancer Carcinoma colorettale metastatico, Colorectal cancer spread at distance Tumore al colon retto diffuso a distanza, Diseases [C] - Cancer [C04] | | | | |
2019-004357-86: Study of chemotherapy combined with ABP 980 in patients with advanced cancer of stomach or gastro-esophageal junction HER2-positive Studio di chemioterapia associata ad ABP 980 in pazienti con tumore dello stomaco o della giunzione gastro-esofagea avanzato HER2 positivo |
|
|
| Ongoing | 2 | 80 | Europe | Kanjinti, [ABP 980], Powder for solution for infusion | GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC), AMGEN | HER2 positive advanced gastric or gastro-esophageal junction cancer Adenocarcinoma gastrico e della giunzione gastro-esofagea avanzato HER 2 positivo, Metastatic tumor of stomach or gastro-esophageal junction Tumore dello stomaco o della giunzione gastro-esofaea metastatico, Diseases [C] - Cancer [C04] | | | | |
2019-002400-40: Prospective study in patients with cancer of the colon or rectum with liver metastasis, of the efficacy and toxicity of standard therapy (chemotherapy + targeted therapy) combined with immunotherapy and internal radiotherapy targeting the liver Etude prospective chez des patients atteints d'un cancer du colon ou du rectum avec des métastase au foie, de l'efficacité et de la toxicité d'une thérapie standard (chimiothérapie + thérapie ciblée) associée à une immunothérapie et une radiothérapie interne ciblant le foie |
|
|
| Not yet recruiting | 2 | 52 | Europe | atezolizumab, RO5541267, Solution for infusion, Concentrate for solution for infusion, CAPÉCITABINE MYLAN, OXALIPLATINE HOSPIRA, Avastin, Tecentriq | Fédération Francophone de Cancérologie Digestive, ROCHE, Boston Scientific | MICROSATELLITE STABLE (MSS) COLORECTAL CANCER WITH LIVER-DOMINANT METASTASIS, METASTATIC COLORECTAL CANCER WITH SPECIFIC MOLECULAR PROFIL (MSS) AND LIVER-DOMINANT METASTASIS, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 274 | Europe, Canada, US, RoW | BMS-986213, Nivolumab, Opdivo, BMS-936558, XELOX, FOLFOX, SOX | Bristol-Myers Squibb | Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction | 08/20 | 01/24 | | |
NCT03783936: Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas |
|
|
| Completed | 2 | 18 | US | Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab | Ashwin Somasundaram, EMD Serono, University of North Carolina, Chapel Hill | Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification | 09/20 | 08/22 | | |
2019-001471-36: Prime RT - using chemotherapy and radiotherapy to charge the immune system making immunotherapies more effective in boosting anti-cancer immune responses in rectal cancer |
|
|
| Not yet recruiting | 2 | 54 | Europe | Durvalumab, Oxaliplatin, Fluorouracil, Folinic Acid, capecitabine, Concentrate for solution for infusion, Solution for injection/infusion, Film-coated tablet, Durvalumab | NHS Greater Glasgow and Clyde, The University of Glasgow, , AstraZeneca | Rectal Cancer., Cancer of the lower end of the large bowel., Diseases [C] - Cancer [C04] | | | | |
2019-002373-59: A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Eine Phase-II-Studie zur Untersuchung von Gemcitabin/Oxaliplatin/Rituximab mit Tafasitamab (MOR-00208) bei Patienten mit aggressivem Lymphom. |
|
|
| Ongoing | 2 | 64 | Europe | Tafasitamab, MOR00208, Lyophilisate for solution for infusion, MINJUVI® 200 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung | University Medical Center of the Johannes Gutenberg University Mainz, Incyte Corporation | Malignant B-cell lymphoma Aggressives B-Zell Lymphom, Malignant Lymphoma Aggressives Lymphom, Diseases [C] - Cancer [C04] | | | | |
2019-002734-37: Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients with Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC) Offene, einarmige Phase II klinische Studie zur Wirksamkeit, Sicherheit und Lebensqualität einer neoadjuvanten Chemotherapie aus liposomalem Irinotecan kombiniert mit Oxaliplatin und 5-Fluorouracil/Folinsäure, gefolgt von kurativer Resektion bei Patienten mit auf die Leber beschränktem oligometastatischen Adenokarzinom des Pankreas (HOLIPANC) |
|
|
| Not yet recruiting | 2 | 150 | Europe | Oxaliplatin, Folinic Acid, 5-Fluorouracil, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Solution for infusion, Onivyde | University of Cologne, SERVIER (Les Laboratoires Servier, France) | Hepatic Oligometastatic Adenocarcinoma of the Pancreas Auf die Leber beschränktes oligometastatisches Adenokarzinom des Pankreas, Hepatic Oligometastatic Adenocarcinoma of the Pancreas Auf die Leber beschränktes oligometastatisches Adenokarzinom des Pankreas, Diseases [C] - Cancer [C04] | | | | |
| Not yet recruiting | 2 | 120 | Europe | Gemkabi, Abraxane, Fluorouracil Accord, Powder and solvent for dispersion for injection, Concentrate for solution for infusion, Powder for suspension for injection, Solution for injection/infusion, Solution for injection, Sonazoid, Gemkabi, Abraxane, Flourouracil Accord, Kalsiumfolinat Pfizer, Oxaliplatin SUN, Irinotecan Accord | Helse Bergen HF, Department of Medicine, National Institutes of Health, The Norwegian Cancer Society, Helse Vest | Histologically verified, locally advanced (nonresectable Stage II/III) or metastatic (Stage IV) adenocarcinoma of the pancreas., Pancreatic cancer. Only patients with inoperable disease will be included, meaning patients who's cancer has grown too much to operate, or spread to other parts of the body., Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 2 | 29 | RoW | Capecitabine, Xeloda, Radiation therapy, mFOLFOX6, Nivolumab, Opdivo | Baruch Brenner, Bristol-Myers Squibb | Rectal Cancer | 04/21 | 10/25 | | |
| Completed | 2 | 218 | Europe | Bevacizumab, Irinotecan, Oxaliplatin, L-Leucovorin, 5-fluorouracil, Atezolizumab | Gruppo Oncologico del Nord-Ovest, Roche Pharma AG | Metastatic Colorectal Cancer | 06/21 | 08/23 | | |
2020-004636-25: Incidence of cardiovascular events in patients with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin after an episode of cardiac angina-related thoracic pain in the adjuvant or metastatic setting. |
|
|
| Not yet recruiting | 2 | 49 | Europe | Lonsurf, oxaliplatin, Tablet, Solution for infusion, Lonsurf, oxaliplatin | GERCOR, Servier | colorectal or oesogastric adenocarcinoma, colorectal or oesogastric adenocarcinoma, Diseases [C] - Cancer [C04] | | | | |
2021-001181-38: Study on the treatment of patients with gastroesophageal cancer with chemotherapy and immunotherapy based on a non-functioning DNA mismatch repair mechanism in the tumour cells Onderzoek naar de behandeling van patiënten met maag-/slokdarmkanker met chemotherapie en immunotherapie op basis van een niet werkend DNA mismatch herstel mechanisme in de tumorcellen |
|
|
| Not yet recruiting | 2 | 25 | Europe | Retifanlimab, INCMGA00012, Solution for infusion | Academic Medical Center, Incyte | Gastroesophageal cancer Oesophagus- en maagcarcinoom, Gastroesophageal cancer Slokdarm- en maagkanker, Diseases [C] - Cancer [C04] | | | | |
2021-000553-40: Study of NIS793 and other novel investigational combinations with SOC anti-cancer therapy for the second line treatment of mCRC Az NIS793 vizsgálata és egyéb új vizsgálati készítmények hagyományos rákellenes kezelésekkel való kombinációja az áttétes kolorektális rák (mCRC) másodvonalbeli kezeléseként |
|
|
| Ongoing | 2 | 190 | Europe | 5-Fluorouracil, oxaliplatin, leucovorin, irinotecan, bevacizumab, NIS793, Concentrate for solution for infusion, Powder for solution for infusion | Novartis Pharma AG, Novartis Pharma AG | metastatic colorectal cancer (mCRC), colorectal cancer, Diseases [C] - Cancer [C04] | | | | |
2020-002715-21: Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy– a Phase II study |
|
|
| Not yet recruiting | 2 | 80 | Europe | Atezolizumab, IMM-101, L01XC32, Concentrate for solution for infusion, Suspension for injection, Tecentriq (R) | AIO-Studien-gGmbH, F. Hoffmann-La Roche Ltd, Immodulon Therapeutics Ltd. | Patients with MSI-high or MMR-deficient stage III colorectal cancer who are ineligible for or who refuse oxaliplatin-based chemotherapy after R0 tumor resection (main study) or planned resection (sub-study), patients with stage III colon or rectum cancer who are ineligible or refuse oxaliplatin-based chemotherape after surgical removal of the tumor (main study) oder the surgery is planned (sub-study), Diseases [C] - Cancer [C04] | | | | |
NCT01191697: CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer |
|
|
| Active, not recruiting | 2 | 37 | US | bevacizumab, Avastin, trastuzumab, Herceptin, oxaliplatin, capecitabine, xeloda | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Genentech, Inc. | Esophageal Cancer, Gastric Cancer | 12/21 | 07/24 | | |
|
NCT02555358: Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study |
|
|
| Completed | 2 | 300 | RoW | docetaxel,0xaliplatin,capecitabine, AISU,AIHENG,AIBIN, oxaliplatin,capecitabine, AIHENG,AIBIN | Qun Zhao, Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer | 12/21 | 06/22 | | |
CLIMB, NCT03698461: Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab |
|
|
| Completed | 2 | 20 | RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin, Oxaliplatin, Levoleucovorin, 5-FU, 5-fluorouracil | Asan Medical Center, Hoffmann-La Roche | Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms, Rectal Neoplasms | 12/21 | 10/23 | | |
NCT04466254: Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 75 | RoW | CPGJ602, cetuximab | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Metastatic Colorectal Cancer | 12/21 | 03/22 | | |
| Recruiting | 2 | 20 | Europe | Atezolizumab, MPDL3280A, Capecitabine, L01BC06, Oxaliplatin, L01XA03, Docetaxel, L01CD02 | The Netherlands Cancer Institute, Hoffmann-La Roche | Stomach Cancer, Gastro Esophageal Junction Cancer | 01/22 | 01/22 | | |
2021-000507-20: Study to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tumor DNA. Estudio para evaluar el efecto de la quimioterapia adyuvante intensiva frente a la estándar en el cáncer de colon localizado con ADN tumoral circulante. |
|
|
| Not yet recruiting | 2 | 164 | Europe | Concentrate for solution for infusion, Powder and solution for solution for injection, Solution for injection/infusion, Film-coated tablet, Irinotecan, OXALIPLATIN, Calcium folinate, FLUORURACIL, Capecitabine | Instituto de Investigación Sanitaria INCLIVA, Instituto de Salud Carlos III | Localised Colon Cancer (stage II-III) Cáncer Colorrectal Localizado (estadio II-III), Colon Cancer (stage II-III) Cáncer Colorrectal (estadio II-III), Diseases [C] - Cancer [C04] | | | | |
NCT05039944: SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies |
|
|
| Terminated | 2 | 7 | RoW | SI-B001, Irinotecan, FOLFIRI Protocol, FOLFOX Protocol | Sichuan Baili Pharmaceutical Co., Ltd. | Colorectal Cancer | 06/22 | 06/22 | | |
2021-002169-16: USE OF CIRCULATING TUMOR DNA TEST TO INTENSIFY POST-OPERATIVE TREATMENT OF PATIENTS WITH RESECTED COLON CANCER. UTILIZZO DEL DNA TUMORALE CIRCOLANTE PER INTENSIFICARE IL TRATTAMENTO POST-OPERATORIO DEI PAZIENTI CON TUMORE DEL COLON OPERATO. |
|
|
| Not yet recruiting | 2 | 459 | Europe | Calcio Levofolinato, Oxaliplatino, Capecitabina, Irinotecan, LONSURF, Fluorouracile, Lonsurf, [Calcio Levofolinato], [Oxaliplatino], [Capecitabina], [Irinotecan], [TAS-102], [Fluorouracile], Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Film-coated tablet, Solution for injection/infusion, Solution for infusion, LONSURF - 15 MG/6,14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER AL/AL - 20 COMPRESSE, LONSURF - 20 MG/8,19 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER AL/AL - 20 COMPRESSE | Fondazione GONO, SERVIER ITALIA SPA, Servier Affaires Médicales, Fondazione GONO, Foundation Medicine Inc | STAGE III AND HIGH-RISK STAGE II RESECTED COLON CANCER PATIENTS. TUMORE DEL COLON RESECATO IN STADIO III O IN STADIO II AD ALTO RISCHIO., RESECTED COLON CANCER Tumore del colon operato, Diseases [C] - Cancer [C04] | | | | |
NCT03549494: Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction |
|
|
| Completed | 2 | 45 | RoW | Ocoxin-Viusid® | Catalysis SL | Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Esophageal Neoplasms, Head and Neck Neoplasms, Gastrointestinal Disease, Digestive System Disease, Esophageal Diseases, Stomach Diseases, Esophagogastric Junction Disorder | 06/22 | 02/23 | | |
NCT04631757: Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 33 | NA | Camrelizumab + SOX + Radiotherapy | Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer | 06/22 | 12/23 | | |
| Recruiting | 2 | 67 | RoW | Camrelizumab combined with SOX/ or apatinib | First Affiliated Hospital Xi'an Jiaotong University, Jiangsu HengRui Medicine Co., Ltd. | Locally Advanced Gastric Cancer | 06/22 | 12/22 | | |
NCT03563248: Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 168 | US | FOLFIRINOX, Losartan, Nivolumab, SBRT, Surgery | Massachusetts General Hospital, Bristol-Myers Squibb, Stand Up To Cancer, Lustgarten Foundation | Pancreatic Cancer | 07/22 | 06/27 | | |
2022-000273-81: Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin versus FOLFOX in patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy |
|
|
| Not yet recruiting | 2 | 118 | Europe | LONSURF, ELVORINE, Coated tablet, Solution for infusion, Capsule, LONSURF, ELOXATINE, FOLINATE DE CALCIUM, 5-Fluorouracil, capecitabine, ELVORINE | UNICANCER, Laboratoire SERVIER | Patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy., Oxaliplatin in combination with trifluridine/tipiracil or 5-fluorouracile in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer, Diseases [C] - Cancer [C04] | | | | |
2021-006512-87: Pembrolizumab and trastuzumab in combination with chemotherapy before and after surgery for patients with HER2-positive gastric cancer - PHERFLOT – |
|
|
| Not yet recruiting | 2 | 30 | Europe | Oxaliplatin, Folinic acid, 5-Fluorouracil, Docetaxel, Solution for infusion, Powder for solution for infusion, Solution for injection/infusion, Solution for injection, Concentrate for solution for infusion, KEYTRUDA® (Pembrolizumab, MK-3475), Ontruzant® (Trastuzumab, OG-9482) | Institut für Klinische Krebsforschung IKF GmbH, MSD Sharp & Dohme GmbH, ORGANON Healthcare GmbH | HER2 positive, localized esophagogastric adenocarcinoma, operable gastric cancer, Diseases [C] - Cancer [C04] | | | | |
QLYY-iCCA-01, NCT06239532: HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | HAIC+TAE, Tislelizumab, Surufatinib | Qilu Hospital of Shandong University, BeiGene | Intrahepatic Cholangiocarcinoma | 05/24 | 12/25 | | |
| Recruiting | 2 | 104 | RoW | AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan, Leucovorin, 5-fluorouracil | Akeso | Metastatic Colorectal Cancer | 12/24 | 12/26 | | |
ICONIC, NCT03399071: Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer |
|
|
| Active, not recruiting | 2 | 44 | Europe | FLOT-A | Royal Marsden NHS Foundation Trust, Merck KGaA, Darmstadt, Germany | Gastric Adenocarcinoma, Oesophageal Adenocarcinoma | 11/22 | 08/25 | | |
NCT01274962: A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer |
|
|
| Completed | 2 | 180 | Canada | FOLFOX, high dose rate endorectal brachytherapy | Sir Mortimer B. Davis - Jewish General Hospital, Sanofi | Operable T2-3N+M0 Rectal Cancer (Stage III) | 12/22 | 12/22 | | |
ALTER-G-001, NCT05262335: Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis |
|
|
| Recruiting | 2 | 116 | RoW | Anlotinib + Oxaliplatin + Capecitabine, Anlotinib + Cisplatin + Paclitaxel/ Docetaxel, Anlotinib + Standard first-line chemotherapy | Ruijin Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Gastrointestinal Tumors | 12/23 | 12/24 | | |
NCT05545436: Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 34 | RoW | Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ), Camrelizumab + SOX / XELOX | Third Affiliated Hospital, Sun Yat-Sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Locally Advanced Gastric Cancer | 12/22 | 06/23 | | |
NCT02581215: Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 84 | US | mFOLFIRINOX, Ramucirumab, Cyramza, Placebo | Walid Shaib, MD, Eli Lilly and Company, Hoosier Cancer Research Network | Pancreatic Cancer | 12/22 | 12/23 | | |
| Completed | 2 | 36 | US | Oxaliplatin+Capecitabine+Pembrolizumab | Duke University, Merck Sharp & Dohme LLC | Gastric Cancer, Esophagus Cancer | 02/23 | 02/23 | | |
AFEMA, NCT03279289 / 2016-004076-21: Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen |
|
|
| Completed | 2 | 170 | Europe | Aflibercept, Irinotecan, folinic acid (dl racemic), 5Fluorouracil, 5-FU | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Sanofi | Metastatic Colorectal Cancer | 02/23 | 02/23 | | |
NCT04894123: Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients |
|
|
| Terminated | 2 | 1 | Europe | Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, Eloxatin | GERCOR - Multidisciplinary Oncology Cooperative Group, Servier | Colorectal Adenocarcinoma, Oesogastric | 02/23 | 02/23 | | |
PanaMa, NCT01991873 / 2012-005422-30: Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 387 | Europe | Maintenance Chemotherapy, Folinic acid + 5-FU (5-Fluorouracil), Panitumumab (Within maintenance phase), Vectibix, mFOLFOX6 (Within re-induction phase), Oxaliplatin + Folinic acid + 5-FU (5-Fluorouracil), Panitumumab (Within re-induction phase) | AIO-Studien-gGmbH, ClinAssess GmbH, Amgen | Metastatic Colorectal Cancer | 02/23 | 02/23 | | |
BTCRC-GI15-015, NCT03283761: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma |
|
|
| Completed | 2 | 39 | US | Nab-paclitaxel 150 mg/m^2, Abraxane®, Oxaliplatin 85 mg/m^2, Eloxatin, 5-FU 1200 mg/m^2 x 2 D, Adrucil, Fluorouracil, Leucovorin 400 mg/m^2 | Al B. Benson, III, MD, Celgene Corporation, Big Ten Cancer Research Consortium | Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer | 12/22 | 01/23 | | |
NCT04908813: Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer |
|
|
| Active, not recruiting | 2 | 150 | RoW | HLX22, Placebo, Trastuzumab, Oxaliplatin, Capecitabine | Shanghai Henlius Biotech | Gastric Cancer | 12/24 | 12/25 | | |
| Recruiting | 2 | 102 | RoW | SHR1459 ；YY-20394, Gemcitabine-Oxaliplatin | Jiangsu HengRui Medicine Co., Ltd. | Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma | 04/23 | 10/23 | | |
2022-001752-42: Durvalumab-based immunotherapy in combination with chemoradiation for patients with early stage esophageal adenocarcinoma |
|
|
| Not yet recruiting | 2 | 32 | Europe | Durvalumab, Oxaliplatin, Calcium Folinate, 5-Fluorouracil, Doxetaxel, Concentrate for solution for infusion, Solution for injection/infusion, Solution for injection, IMFINZI | Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, AstraZeneca GmbH | T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery, Early stage esophageal cancer, Diseases [C] - Cancer [C04] | | | | |
NCT04661150: A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction |
|
|
| Active, not recruiting | 2 | 41 | RoW | Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Capecitabine, Oxaliplatin | Hoffmann-La Roche | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/23 | 08/26 | | |
NCT03336216 / 2018-000339-28: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer |
|
|
| Completed | 2 | 206 | Europe, Canada, Japan, US, RoW | Cabiralizumab, BMS-986227, FPA008, Nab-paclitaxel, Abraxane, Onivyde, irinotecan liposome, Nivolumab, Opdivo, BMS-936558, Fluorouracil, 5-Fluorouracil, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan Hydrochloride | Bristol-Myers Squibb | Advanced Pancreatic Cancer | 06/23 | 06/23 | | |
|
HCRN GI16-288, NCT03547999: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC |
|
|
| Active, not recruiting | 2 | 78 | US | mFOLFOX6, MVA-BN-CV301, Modified Vaccinia Ankara, CV301, FPV-CV301, Fowl Pox Virus, Nivolumab, Opdivo | Patrick Boland, Bavarian Nordic, Hoosier Cancer Research Network, Bristol-Myers Squibb | Metastatic Colorectal Cancer | 03/24 | 12/24 | | |
|
NCT03451331: Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer |
|
|
| Completed | 2 | 49 | US | Nivolumab, OPDIVO®, Gemcitabine, Gemzar, Carboplatin, Paraplatin®, Oxaliplatin, Eloxatin | Matthew Galsky, Bristol-Myers Squibb, Hoosier Cancer Research Network | Metastatic Urothelial Cancer | 06/23 | 07/23 | | |
| Active, not recruiting | 2 | 20 | Europe | NALRINOX combination | Fundación de investigación HM, Syntax for Science, S.L | Resectable Pancreatic Ductal Adenocarcinoma | 08/23 | 11/23 | | |
NCT04479527: Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 34 | NA | Camrelizumab, Apatinib Mesylas | Beijing Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Hepatocellular Carcinoma | 08/23 | 12/23 | | |
2018-000406-36: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE) |
|
|
| Not yet recruiting | 2 | 240 | Europe | nivolumab, ipilimumab, CISPLATIN, CAPECITABINE, Fluorouracil, EPIRUBICIN, Oxaliplatin, LEUCOVORIN, Docetaxel, L01XC11, Concentrate for solution for infusion, Film-coated tablet, Opdivo, Yervoy | European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for the Research and Treatment of Cancer, BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION | Gastric, lower esophageal or GE-junction adenocarcinoma, Stomach cancer and cancer of the lower part of the esophageus, Diseases [C] - Cancer [C04] | | | | |
NCT05546411: A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer |
|
|
| Terminated | 2 | 8 | US | mFOLFIRINOX, 5-Fluorouracil (5-FU), Adrucil, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, Camptothecin-11, CPT-1, Leucovorin, Calcium Leucovorin, Citrovorum Factor, Folinic Acid, NIS793, Chemoradiation, Surgery | Kimberly Perez, MD, Novartis | Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma | 08/23 | 10/23 | | |
NEO-Nal- IRI, NCT03483038: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 45 | US | Liposomal Irinotecan, ONIVYDE, FOLFOX regimen | University of Florida, Ipsen | Pancreatic Adenocarcinoma | 09/23 | 12/24 | | |
NCT05594381: A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma. |
|
|
| Not yet recruiting | 2 | 90 | NA | Sintilimab, Oxaliplatin, Tegafur, Radical gastrectomy with D2 lymph node dissection | The First Affiliated Hospital with Nanjing Medical University, Innovent Biologics (Suzhou) Co. Ltd., Nanjing Geneseeq Technology Inc | Gastric Cancer | 09/23 | 10/25 | | |
N-PRC, NCT05576480: SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer |
|
|
| Not yet recruiting | 2 | 55 | NA | Short-course radiotherapy, Penpulimab, PD-1 monoclonal antibody, CAPEOX, Capecitabine and oxaliplatin, TME surgery | Ruijin Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rectal Cancer, Locally Advanced | 10/23 | 12/26 | | |
NCT04933227: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) |
|
|
| Terminated | 2 | 29 | RoW | Atezolizumab, Tecentriq, Tiragolumab, Oxaliplatin, Capecitabine | Hoffmann-La Roche | Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 11/23 | 11/23 | | |
OPRA, NCT02008656: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management |
|
|
| Active, not recruiting | 2 | 358 | US | Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin, Capecitabine (Xeloda®), intensity modulated radiotherapy (IMRT), Quality of Life Questionnaires, DRE-Endoscopy | Memorial Sloan Kettering Cancer Center, Colon and Rectal Surgery Inc., The Cleveland Clinic, John Muir Health, Oregon Health and Science University, St. Joseph Hospital of Orange, University of California, Irvine, University of California, San Francisco, University of Chicago, University of South Florida, University of Vermont, University of Washington, Medstar Health Research Institute, Washington University School of Medicine, Creighton University Medical Center, The Methodist Hospital Research Institute, University of Rochester, University of Virginia, St. Paul's Hospital, St. Joseph, Florida, Cleveland Clinic Florida, University of Colorado, Denver, University of Michigan | Rectal Cancer | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 58 | US | APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days | University of Texas Southwestern Medical Center, Apexigen America, Inc. | Locally Advanced Rectal Adenocarcinoma | 09/25 | 09/25 | | |
NCT03861702: Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: |
|
|
| Active, not recruiting | 2 | 28 | US | FOLFOX regimen, Liposomal Irinotecan, nal-Irinotecan | Nelson Yee, Ipsen | Locally Advanced Pancreatic Carcinoma(LAPC) | 08/23 | 08/24 | | |
NCT05047991: Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 153 | NA | Irinotecan Liposome Injection, Fluorouracil, Leucovorin, Oxaliplatin, Nab paclitaxel, Gemcitabine | CSPC Ouyi Pharmaceutical Co., Ltd. | Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic | 11/23 | 11/24 | | |
NCT06155383: Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. |
|
|
| Recruiting | 2 | 90 | RoW | Capecitabine, oxaliplatin, Disitamab Vedotin, RC48, Toripalimab, JS001 | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 12/27 | | |
| Recruiting | 2 | 40 | US | FOLFOX/ nal-IRI, Paclitaxel, Abraxane®., Carboplatin, Paraplatin, Proton Radiation Therapy | Massachusetts General Hospital, Ipsen | Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer | 12/23 | 12/27 | | |
NCT05068206: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx |
|
|
| Recruiting | 2 | 120 | RoW | AK105 injection, Anlotinib hydrochloride capsule, CapeOX, Bevacizumab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unresectable Metastatic Colorectal Cancer | 12/23 | 06/24 | | |
CCGLC-011, NCT06187961: Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Lenvatinib plus cadonilimab, levima plus cadonilimab | Tongji Hospital, Geneplus-Beijing Co. Ltd. | Hepatocellular Carcinoma Non-resectable | 12/25 | 06/26 | | |
NCT06256328: A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) |
|
|
| Recruiting | 2 | 210 | Japan, RoW | ONO-4578, Oxaliplatin, Capecitabine, S-1, Tegafur-gimeracil-oteracil potassium, Nivolumab, Opdivo, Placebo | Ono Pharmaceutical Co. Ltd | Gastric Cancer | 11/25 | 12/27 | | |
| Recruiting | 2 | 214 | Europe | Regorafenib, panitumumab, Panitumumab, regorafenib | Gruppo Oncologico del Nord-Ovest, Bayer, Amgen | Colorectal Cancer | 12/24 | 06/25 | | |
NCT05246982: HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 2 | 40 | RoW | HLX07+HLX10+oxaliplatin+capecitabine, HLX07 | Shanghai Henlius Biotech | Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) | 12/23 | 03/24 | | |
TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 2 | 106 | Europe | FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi | GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics | Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer | 12/23 | 12/24 | | |
TRIPLET, NCT04191889: A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification |
|
|
| Recruiting | 2 | 47 | RoW | Hepatic Arterial Infusion combined with Apatinib and Camrelizumab | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | C-staged Hepatocellular Carcinoma in BCLC Classification | 12/23 | 12/25 | | |
NCT04609176: Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 64 | RoW | Camrelizumab plus Apatinib and SOX, Camrelizumab plus Apatinib | Peking University, Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer | 12/23 | 12/24 | | |
ULTIMA, NCT04611724: A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer |
|
|
| Recruiting | 2 | 35 | RoW | FOLFIRINOX | Asan Medical Center, Green Cross Corporation, Boryung Pharmaceutical Co., Ltd | Urachal Cancer | 12/23 | 09/24 | | |
| Recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/27 | | |
NCT05052931: Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 10 | RoW | Nab-paclitaxel combined with oxaliplatin and S-1 | Jianjun Yang, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/23 | 12/23 | | |
NCT05077800: FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer |
|
|
| Recruiting | 2 | 70 | US | FOLFIRNINOX, Losartan, Cozaar, 9-ING-41 | Colin D. Weekes, M.D., PhD, Actuate Therapeutics Inc., Lustgarten Foundation | Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic | 12/25 | 07/26 | | |
SILAR, NCT05450029: Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 51 | RoW | Sintilimab, Chemoradiotherapy and PD1 inhibitor | Yanhong Deng, GeneCast Biotechnology Co., Ltd. | Rectal Cancer | 01/24 | 01/27 | | |
NCT05132504: Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer |
|
|
| Recruiting | 2 | 30 | US | Pembrolizumab, keytruda, Folfirinox, mFolfirinox | Baylor College of Medicine, Merck Sharp & Dohme LLC, The Methodist Hospital Research Institute | Pancreatic Ductal Adenocarcinoma | 07/24 | 12/24 | | |
Averectal, NCT03503630: Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 44 | RoW | COMPOUND 2055269, Radiation Therapy, mFOLFOX, Total Mesorectal Excision | Ali Shamseddine, Merck KGaA, Darmstadt, Germany, Phoenix Clinical Research | Locally Advanced Rectal Cancer | 03/21 | 07/24 | | |
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer |
|
|
| Completed | 2 | 124 | Europe | Aflibercept + mLV5FU2, mFOLFOX7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi | Colorectal Cancer | 02/24 | 02/24 | | |
2021-005326-23: Evaluation of the efficacy of donepezil in the treatment of oxaliplatin-induced peripheral neuropathy EVALUATION DE L’EFFICACITE DU DONEPEZIL DANS LE TRAITEMENT DES NEUROPATHIES PERIPHERIQUES INDUITES PAR L’OXALIPLATINE |
|
|
| Not yet recruiting | 2 | 80 | Europe | DONEPEZIL, Tablet, Donepezil | CHU de Clermont-Ferrand, Institut National du Cancer (INCa) | Oxaliplatine-induced peripheral neuropathy Neuropathie périphérique induite par l'oxaliplatine, Oxaliplatine-induced peripheral neuropathy Neuropathie périphérique induite par l'oxaliplatine, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT04757363: A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer |
|
|
| Active, not recruiting | 2 | 39 | US | regorafenib, nivolumab, FOLFOX chemotherapy with oxaliplatin | Memorial Sloan Kettering Cancer Center, Bayer, Bristol-Myers Squibb | Esophagogastric Cancer, HER2-Negative | 02/25 | 02/25 | | |
EGIA-003, NCT06225843: Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis |
|
|
| Recruiting | 2 | 17 | Canada | Sotevtamab, AB-16B5, FOLFOX | Alethia Biotherapeutics | Metastatic Colorectal Cancer | 03/25 | 06/25 | | |